The Company also provides an update on the Silicon Valley Bank convertible debt facility Including the new C$12 million convertible debt facility, Eupraxia anticipates it has sufficient cash to fund… Read More
Cerevel’s clinical-stage assets complement AbbVie’s emerging neuroscience pipeline and leading on-market brands in psychiatry, migraine and Parkinson’s disease Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be… Read More
SAN JOSE, CA – Stryker (NYSE:SYK), a global leader in medical technologies, announced that it has completed the acquisition of MOLLI Surgical Inc., a privately held company specializing in the… Read More
VANCOUVER, BC – STEMCELL Technologies has commercially launched the CellPore™ Transfection System, providing a groundbreaking new technology with the potential to advance cell engineering research and the development of novel… Read More
VANCOUVER, BC – AbCellera (Nasdaq: ABCL) announced that it has expanded its existing collaboration with Eli Lilly and Company (Lilly) to discover therapeutic antibodies for programs in immunology, cardiovascular disease,… Read More
